Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, OH.
Department of Pediatrics, Children's National Hospital, George Washington University School of Medicine, Washington, DC.
Pediatr Crit Care Med. 2022 Apr 1;23(4):245-254. doi: 10.1097/PCC.0000000000002917. Epub 2022 Feb 23.
Characterize the use of inhaled nitric oxide (iNO) for pediatric cardiac patients and assess the relationship between patient characteristics before iNO initiation and outcomes following cardiac surgery.
Observational cohort study.
PICU and cardiac ICUs in seven Collaborative Pediatric Critical Care Research Network hospitals.
Consecutive patients, less than 18 years old, mechanically ventilated before or within 24 hours of iNO initiation. iNO was started for a cardiac indication and excluded newborns with congenital diaphragmatic hernia, meconium aspiration syndrome, and persistent pulmonary hypertension, or when iNO started at an outside institution.
None.
Four-hundred seven patients with iNO initiation based on cardiac dysfunction. Cardiac dysfunction patients were administered iNO for a median of 4 days (2-7 d). There was significant morbidity with 51 of 407 (13%) requiring extracorporeal membrane oxygenation and 27 of 407 (7%) requiring renal replacement therapy after iNO initiation, and a 28-day mortality of 46 of 407 (11%). Of the 366 (90%) survivors, 64 of 366 patients (17%) had new morbidity as assessed by Functional Status Scale. Among the postoperative cardiac surgical group (n = 301), 37 of 301 (12%) had a superior cavopulmonary connection and nine of 301 (3%) had a Fontan procedure. Based on echocardiographic variables prior to iNO (n = 160) in the postoperative surgical group, right ventricle dysfunction was associated with 28-day and hospital mortalities (both, p < 0.001) and ventilator-free days (p = 0.003); tricuspid valve regurgitation was only associated with ventilator-free days (p < 0.001), whereas pulmonary hypertension was not associated with mortality or ventilator-free days.
Pediatric patients in whom iNO was initiated for a cardiac indication had a high mortality rate and significant morbidity. Right ventricular dysfunction, but not the presence of pulmonary hypertension on echocardiogram, was associated with ventilator-free days and mortality.
描述儿科心脏病患者使用吸入一氧化氮(iNO)的情况,并评估 iNO 治疗前患者特征与心脏手术后结局之间的关系。
观察性队列研究。
七个协作儿科危重病研究网络医院的 PICU 和心脏 ICU。
在开始 iNO 治疗之前或之后 24 小时内接受机械通气的,年龄小于 18 岁的连续患者。iNO 因心脏原因开始治疗,并排除先天性膈疝、胎粪吸入综合征和持续性肺动脉高压的新生儿,或当 iNO 在外部机构开始时。
无。
根据心功能障碍,407 例患者开始使用 iNO。心功能障碍患者接受 iNO 治疗的中位数为 4 天(2-7 天)。发病率很高,51/407(13%)需要体外膜氧合,27/407(7%)需要肾脏替代治疗,28 天死亡率为 46/407(11%)。在 366 例(90%)幸存者中,64/366 例(17%)根据功能状态量表评估出现新的发病率。在术后心脏手术组(n=301)中,37/301(12%)行上腔静脉-肺动脉吻合术,9/301(3%)行 Fontan 手术。在术后心脏手术组的 301 例患者中(n=160),根据 iNO 治疗前的超声心动图变量,右心室功能障碍与 28 天死亡率和院内死亡率(均,p<0.001)和呼吸机脱机率(p=0.003)相关;三尖瓣反流仅与呼吸机脱机率(p<0.001)相关,而肺动脉高压与死亡率或呼吸机脱机率无关。
因心脏原因开始 iNO 治疗的儿科患者死亡率和发病率很高。右心室功能障碍,但超声心动图上不存在肺动脉高压,与呼吸机脱机率和死亡率相关。